US Patent Issued to BioCryst Pharmaceuticals on Dec. 23 for "Process-scale synthesis of a plasma kallikrein inhibitor" (Alabama Inventors)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,503,443, issued on Dec. 23, was assigned to BioCryst Pharmaceuticals Inc. (Durham, N.C.).

"Process-scale synthesis of a plasma kallikrein inhibitor" was invented by Yahya El-Kattan (Vestavia Hills, Ala.) and Yarlagadda S. Babu (Birmingham, Ala.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are methods of preparing Compound I, and salts thereof. The methods of preparing Compound I are suitable for use on process scale."

The patent was filed on Aug. 5, 2020, under Application No. 17/632,585.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fn...